goldenstrand, are you saying you sold out last Friday?
I forgot to say that the CDMRP comments on Gulf War Illness are on page 10.
If anyone is interested in learning more about the prior FY 2010 CDMRP award discussed above - (“In a subsequent FY 2010 award, the mouse model was used to assess neurobehavioral outcome following treatment with the anti-inflammatory anatabine”) , simply google – GW100076 and don’t forget to read both the public and technical abstract.
This was the CDMRP award prior to the most recent CDMRP award (GW140159).
As can be seen, GW100076 research involved the creation of a mouse model and testing of anatabine while GW140159 makes the transition to human testing with anatabine.
Yahoo will not allow links to be posted but the abstracts can be found by googling the titles above.
Related to the above, here is a title to a Neuroscience 2014 presentation.
DELAYED TREATMENT WITH ANATABINE AFTER REPETITIVE MILD TBI NORMALIZES SPATIAL MEMORY IMPAIRMENT.
“Traumatic brain injury (TBI) is a serious illness which on average strikes one person every 15 seconds in the US. TBI carries long term consequences, even after mild TBI, which are the most common and comprise as many as 75% of all TBI cases… We have continued to characterize the surviving mice using a crossover study design…. Anatabine shows strong potential at improving memory following TBI, and may have a long therapeutic window, even to chronic timepoints; these data support further preclinical exploration of anatabine as a treatment for TBI.”
The full abstracts can be found by googling the titles above
mTBI is mild traumatic brain injury.
Here are three research abstracts on the topic of mTBI and Anatabine.
SPATIAL MEMORY NORMALIZATION AFTER TREATMENT WITH ANATABINE BEGINNING NINE MONTHS AFTER REPETITIVE MILD TBI
Ferguson S, Mouzon B, Abdullah L, Crynen G, Paris D, Mullan M, Crawford F.
Annual Meeting National Neurotrauma Society Symposium 2014.
“Anatabine shows potential at improving memory following TBI, mitigating against pathogenic neuroinflammation, and may have a long therapeutic window.”
TREATMENT WITH ANATABINE SIGNIFICANTLY IMPROVES CHRONIC OUTCOME IN A MOUSE MODEL OF REPETITIVE MILD TBI
Ferguson S, Mouzon B, Ojo J, Crynen G, Mathura V, Mullan M, Crawford F.
Annual Meeting Society for Neuroscience 2013.
“Daily treatment with the anti-inflammatory dietary supplement anatabine significantly improved long-term spatial memory after r-mTBI at a 6 month timepoint. Although anatabine treated mice still showed significant spatial learning deficits 6 months after TBI, spatial memory was significantly improved compared to untreated controls.”
TBI-INDUCED SPATIAL MEMORY LOSS IS AVERTED BY TREATMENT WITH THE DIETARY SUPPLEMENT ANATABINE
Ferguson S, Mouzon B, Ojo J, Bishop A , Crynen G, Phillips J, Mathura V, Mullan M, Crawford F.
Annual Meeting Society for Neuroscience 2012.
“Anatabine treatment appeared to completely prevent the loss of spatial memory retention following severe TBI. Further study of this promising treatment is warranted and will include treatment in a mild closed head injury model as well as long term outcome from injury...”
The Congressional oversight committee that oversees the funding awarded by CDMRP (Congressionally Directed Medical Research Program), requested that CDMRP provide a breakdown of basic vs advanced research funding. The motive behind this request from the oversight committee, headed by Senator John McCain, was to confirm that the money being spent is leading to treatments, not just basic research.
Here is what CDMRP said in their response letter, with date stamp of 3/9/2016, about anatabine and GWI.
“Gulf War Illness: Supported an FY 2008 award to develop and characterize a mouse model of exposure to agents associated with GWI. In a subsequent FY 2010 award, the mouse model was used to assess neurobehavioral outcome following treatment with the anti-inflammatory anatabine. These investigations led to a FY 2014 clinical evaluation of anatabine in a small population of GWI patients.”
To read the full letter;
Google - Peer Reviewed Medical Research Program - Health.mil Anatabine
Then click on the pdf
Goggle - GW140159
to see the funding awarded by CDMRP
drummLIAR, and several of his alter ID's, like to make long winded posts.
The funny thing is that no one actually reads them, but he thinks they do.
I blame the yaks,
they just won't herd properly.
And don't forget to pay homage to drumLIAR
He gets cranky when homage is not paid.
trying to convince shareholders that everything is hopeless, endless dilution, the scientific research means nothing, the yaks won't herd properly, the air is thin, it's just time to sell.....
Why so many posts wanting you to sell a 2 cent stock?
Chronic Anatabine Treatment Reduces Alzheimer’s Disease (AD) – Like Pathology and Improves Socio-Behavioural Deficits in a Transgenic Mouse Model of AD
Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice
Effects of anatabine at relevant human nicotinic receptor subtypes in vitro and on craving and C-reactive protein in heavy smokers
Amelioration of experimental autoimmune encephalomyelitis by anatabine
Anti-inflmmatory activity of anatabine via inhibition of STAT3 phosphorylation.
Anatabine ameliorates experimental autoimmune thryriditis
Anatabine lowers Alzheimer's Aβ production in vitro and in vivo.
DrummLIAR insists JW is still in charge.
Look in the mirror and ask DrummLIAR.
All answers on this board come from DrummLIAR.
So in DrummLIARS world he has the strongest negotiating position.
Just remember to pay homage when you look in the mirror.
DrummLIAR insists JW is pulling the strings.
Just get a couple of coffee cans and a string and give him a call?
So it appears the answer is yes, the Japanese patent can be licensed by Rock Creek for exclusive use in Japan for either supplement or pharmaceutical use depending on how the contract is written.
Now watch DrummLIAR and his other ID's jump in and try to deflect and change the subject, because if Rock Creek does license this patent out, it will generate revenue and that will destroy the short basher narrative.